top of page

DISRUPT Networking Evening Oct. 11, 2022

Updated: Dec 15, 2022

We had a kick-off networking event with the DISRUPT team and guests that included directors from Columbia, Mount Sinai, and Einstein/Montefiore Cancer Centers, as well as City College of New York.





 
 
 

Recent Posts

See All
NCI-2025-04391

A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy andSafety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants withResected or Unresec

 
 
 
NCI-2025-05085

A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB1305 in Participants with Advanced/Metastatic Solid Tumors This Phase 2 , multicenter, open-label research study i

 
 
 
NCI-2025-07002

A Phase 1b, Two-Part Study of Tolododekin Alfa (ANK-101) in Combination with an Anti-PD-1/PD-L1 Antibody in Participants with Advanced Non-Small Cell Lung Cancer This Phase 1b, two-part research study

 
 
 

Comments

bottom of page